23rd Congress of the European Hematology Association (EHA) - X4 Pharmaceuticals

23rd Congress of the European Hematology Association (EHA)

23rd Congress of the European Hematology Association (EHA)

June 2018

Phase 2 Study of X4P-001: A Targeted Oral Therapy for Patients with WHIM Syndrome

© 2023 X4 Pharmaceuticals, Inc. All rights reserved. Terms of Use | Privacy Policy